Sun Pharma announces successful completion of Opiates business acquisition in Australia

Sun Pharma now offers a rich basket of Opiates product line in addition to a large API portfolio and dosage formulations covering a broad range of chronic and acute prescription drugs.

Sun Pharmaceutical Industries Ltd begins the integration of its Opiates business in Australia following the successful completion of this acquisition from GSK (announced in March 2015). This acquisition fortifies Sun Pharma’s global position with two Opiates manufacturing facilities in Port Fairy & Latrobe (both in Australia) complementing its current API manufacturing footprint globally.

Sun Pharma now offers a rich basket of Opiates product line in addition to a large API portfolio and dosage formulations covering a broad range of chronic and acute prescription drugs. The acquisition also brings a specialized team to drive business growth.

The Opiates acquisition allows Sun Pharma to:

• Significantly expands its narcotics raw material (NRM) market share.
• Enhance Opiate Alkaloids portfolio and depth in Global opiates market.

Strengthen its strategic position in the global Opiates business.Welcoming the Opiates team in Australia, Anil Kumar Jain, CEO – API Business, Sun Pharma said, “The successful completion of this acquisition enables us to leverage our unique position in the global Opiates business by capitalizing our global footprint and global ranking in the specialty generics market. Sun Pharma stays committed to uncompromised product quality, 100% compliance and innovation.”

Over the last few months, the Opiates & Sun Pharma teams put together a transition plan to oversee the implementation of the functional integration of Opiates business. The transition process will emphasize on aligning best functional requirements and leveraging employee talents in this business.